Insight Molecular Diagnostics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.1M | $1.9M | $1.5M | $958,000 | $2.2M |
| Cost of revenue | $1.8M | $1.1M | $1.0M | $880,000 | $697,000 |
| Gross profit | $2.3M | $740,000 | $413,000 | -$18,000 | $1.4M |
| Research and development | $15.9M | $9.8M | $9.3M | $7.3M | $5.0M |
| Operating expenses | $53.4M | $61.8M | $25.5M | $18.0M | $55.1M |
| Operating income | -$51.1M | -$61.0M | -$25.1M | -$18.0M | -$53.7M |
| Pretax income | — | -$60.7M | -$24.9M | -$18.6M | -$52.9M |
| Income tax expense | $0 | $0 | $0 | — | -$9.3M |
| Net income | -$50.2M | -$60.7M | -$27.8M | -$72.9M | -$64.1M |
| Balance Sheet | |||||
| Cash and equivalents | $11.6M | $8.6M | $9.4M | $20.0M | $32.9M |
| Current assets | $15.3M | $11.8M | $10.7M | $25.5M | $39.1M |
| Total assets | $25.8M | $35.1M | $74.9M | $100.1M | $159.6M |
| Current liabilities | $12.1M | $7.3M | $7.2M | $12.1M | $14.1M |
| Total liabilities | $57.2M | $47.4M | $49.3M | $60.5M | $94.3M |
| Stockholders' equity | -$31.5M | -$12.3M | $20.5M | $34.3M | $65.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$22.2M | -$20.7M | -$23.3M | -$45.6M | -$35.9M |
| Depreciation and amortization | $2.2M | $1.6M | $1.7M | $1.5M | $844,000 |
| Stock-based compensation | $2.2M | $1.8M | $2.8M | $10.0M | $6.8M |
| Capital expenditure | $3.2M | $516,000 | $281,000 | $4.3M | $2.2M |
| Free cash flow | -$25.4M | -$21.2M | -$23.6M | -$49.9M | -$38.2M |
| Impairments | $14.6M | $169,000 | $1.3M | $18.7M | — |
Shares outstanding 32.3M
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.